Savara Inc Deferred Tax Assets, Gross
Savara Inc (SVRA) had Deferred Tax Assets, Gross of $143.15 million as of 2025-12-31, per its 10-K filed 2026-03-13.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsGross · last filed 2026-03-13
- 2025-12-31: Deferred Tax Assets, Gross $143.15M.
- 2024-12-31: Deferred Tax Assets, Gross $108.11M.
- 2023-12-31: Deferred Tax Assets, Gross $74.79M.
- 2022-12-31: Deferred Tax Assets, Gross $51.23M.
| Period end | Deferred Tax Assets, Gross | Deferred Tax Assets, Gross as first filed |
|---|---|---|
| 2025-12-31 | $143.15M 10-K · filed 2026-03-13 | |
| 2024-12-31 | $108.11M 10-K · filed 2026-03-13 | |
| 2023-12-31 | $74.79M 10-K · filed 2025-03-27 | |
| 2022-12-31 | $51.23M 10-K · filed 2024-03-07 | |
| 2021-12-31 | $48.35M 10-K · filed 2023-03-30 | |
| 2020-12-31 | $59.24M 10-K · filed 2022-03-30 | |
| 2019-12-31 | $47.07M 10-K · filed 2021-03-10 | |
| 2018-12-31 | $34.64M 10-K · filed 2020-03-12 | |
| 2017-12-31 | $23.32M 10-K · filed 2019-03-13 | |
| 2016-12-31 | $15.19M 10-K · filed 2018-03-14 | $72.93M 10-K · filed 2017-03-06 |
| 2015-12-31 | $55.23M 10-K · filed 2017-03-06 | |
| 2014-12-31 | $33.36M 10-K · filed 2016-03-14 | |
| 2013-12-31 | $17.14M 10-K · filed 2015-03-24 | $17.14M 10-K · filed 2014-03-26 |
| 2012-12-31 | $10.17M 10-K · filed 2014-03-26 | |
| 2011-12-31 | $21.58M 10-K · filed 2013-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B |